Content
Executive summary
Chapter 1: Chugai Pharmaceutical Company Limited
Corporate structure
Geographical breakdown
Human pharmaceuticals
Commercial collaborations
Research & development
Corporate and financial data
Chapter 2: Daiichi Pharmaceutical Co. Ltd
Corporate structure
Geographical breakdown
Human pharmaceuticals
Quinolone antibiotics
Cardiovascular and respiratory
Commercial collaborations
Research & development
Corporate and financial data
Chapter 3: Eisai Company Limited
Corporate structure
Geographical breakdown
Human pharmaceuticals
CNS treatments
Gastrointestinal
Other product lines
Commercial collaborations
Research & development
Corporate and financial data
Chapter 4: Fujisawa Pharmaceutical Company Limited
Corporate structure
Geographical breakdown
Human pharmaceuticals
Antibiotics and biologicals
Metabolic agents
Other product lines
Commercial collaborations
Research & development
Corporate and financial data
Chapter 5: Kyowa Hakko Kogyo Company Limited
Corporate structure
Geographical breakdown
Human pharmaceuticals
Commercial collaborations
Research & development
Corporate and financial data
Chapter 6: Sankyo Company Limited
Corporate structure
Geographical breakdown
Human pharmaceuticals
Commercial collaborations
Research & development
Corporate and financial data
Chapter 7: Shionogi & Company Limited
Corporate structure
Geographical breakdown
Human pharmaceuticals
Commercial collaborations
Research & development
Corporate and financial data
Chapter 8: Takeda Chemical Industries Limited
Corporate structure
Geographical breakdown
Human pharmaceuticals
Antibiotics
Gastrointestinal
Other product lines
Commercial collaborations
Research & development
Corporate and financial data
Chapter 9: Tanabe Seiyaku Company Limited
Corporate structure
Geographical breakdown
Human pharmaceuticals
Cardiovasculars
Other product lines
Commercial collaborations
Research & development
Corporate and financial data
Chapter 10: Yamanouchi Pharmaceutical Company Limited
Corporate structure
Geographical breakdown
Human pharmaceuticals
Gastrointestinal
Benign prostatic hyperplasia
Cardiovasculars
Other product lines
Commercial collaborations
Research & development
Corporate and financial data
List Of Tables
Table 1: Japanese domiciled pharmaceutical companies - sales performance (fiscal 1999 data)
Table 2: Japanese domiciled pharmaceutical companies - domestic sales (fiscal 1999 data)
Table 3: Japanese domiciled pharmaceutical companies - pharmaceutical R&D expenditure (fiscal 1999 data)
Table 4: Japanese domiciled pharmaceutical companies
Chugai Pharmaceutical Company Limited
Table 1.1: Business segment analysis (year end 31 March)
Table 1.2: Human pharmaceuticals - major product performance (fiscal 1999)
Table 1.3: Major commercial agreements
Table 1.4: Financial data
Daiichi Pharmaceutical Co., Ltd
Table 2.1: Business segment analysis (year end 31 March)
Table 2.2: Geographical sales analysis
Table 2.3: Human pharmaceuticals - major product performance (fiscal 1999)
Table 2.4: Major commercial agreements
Table 2.5: Novel agents in late stage clinical development
Table 2.6: Financial data
Eisai Company Limited
Table 3.1: Business segment analysis (year end 31 March)
Table 3.2: Geographical sales analysis
Table 3.3: Human pharmaceuticals - major product performance (fiscal 1999)
Table 3.4: Major commercial agreements
Table 3.5: Financial data
Fujisawa Pharmaceutical Company Limited
Table 4.1: Business segment analysis (year end 31 March)
Table 4.2: Geographical sales analysis
Table 4.3: Major therapy area sales
Table 4.4: Human pharmaceuticals - major product performance (fiscal 1999)
Table 4.5: Major commercial agreements
Table 4.6: Novel agents in late stage clinical development
Table 4.7: Financial data
Kyowa Hakko Kogyo Company Limited
Table 5.1: Business segment analysis (year end 31 March)
Table 5.2: Human pharmaceuticals - major product performance (fiscal 1999)
Table 5.3: Major commercial agreements
Table 5.4: Novel agents in late stage clinical development
Table 5.4: Financial data
Sankyo Company Limited
Table 6.1: Business segment analysis (year end 31 March)
Table 6.2: Geographical sales analysis
Table 6.3: Human pharmaceuticals - major product performance (fiscal 1999)
Table 6.4: Major commercial agreements
Table 6.5: Novel agents in late stage clinical development
Table 6.6: Financial data
Shionogi & Company Limited
Table 7.1: Business segment analysis (year end 31 March)
Table 7.2: Human pharmaceuticals - major product performance (unconsolidated data)
Table 7.3: Major commercial agreements
Table 7.4: Novel agents in late stage clinical development
Table 7.5: Financial data
Takeda Chemical Industries Limited
Table 8.1: Business segment analysis (year end 31 March)
Table 8.2: Major commercial agreements
Table 8.3: Novel agents in late stage clinical development
Table 8.4: Financial data
Tanabe Seiyaku Company Limited
Table 9.1: Business segment analysis (year end 31 March)
Table 9.2: Prescription pharmaceuticals - major product performance (fiscal 1999, non-consolidated data)
Table 9.3: Major commercial agreements
Table 9.4: Novel agents in late stage clinical development
Table 9.5: Financial data
Yamanouchi Pharmaceutical Company Limited
Table 10.1: Business segment analysis (year end 31 March)
Table 10.2: Geographical sales analysis
Table 10.3: Prescription pharmaceuticals - major product performance (fiscal 1999)
Table 10.4: Major commercial agreements
Table 10.5: Novel agents in late stage clinical development
Table 10.6: Financial Data
|
TABLE OF CONTENTS
